Cynthia X. Ma, MD, PhD, on Metastatic Breast Cancer: Early Results on Copanlisib, Fulvestrant, and Abemaciclib
2023 SABCS
Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, discusses phase I findings showing the safety and tolerability of copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer. Preliminary antitumor activity, which was observed, will be further examined in the phase II trial (ClinicalTrials.gov identifier NCT03939897) (Abstract PS17-06).
The ASCO Post Staff
Nadia Harbeck, MD, PhD, of LMU University Hospital and Ludwig Maximilian University of Munich, and Daniel Kates-Harbeck, of the West German Study Group and an MD Candidate at Ludwig Maximilian University of Munich, discuss a learning-based neural network developed by Mr. Kates-Harbeck to predict treatment outcomes in early breast cancer as well as potentially other tumor types (Abstract PO 04 1-10).
The ASCO Post Staff
Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses an exploratory analysis of CheckMate 7FL which showed that patients with PD-L1–positive, high-risk, estrogen receptor–positive, HER2-negative primary breast cancer may achieve substantial pathologic complete response rates with the addition of nivolumab to neoadjuvant chemotherapy (Abstract GS01-01).
The ASCO Post Staff
Seema Khan, MD, of Northwestern University and the Robert H. Lurie Comprehensive Cancer Center, discusses the 5-year clinical outcomes of ECOG-ACRIN 4112, a prospective trial that supports the omission of radiotherapy after surgery in patients with ductal carcinoma in situ who have a low DCIS score and its use in patients with intermediate/high DCIS scores (Abstract GS03-01).
The ASCO Post Staff
Eleftherios P. Mamounas, MD, of Orlando Health Cancer Institute, discusses primary outcomes from the NRG Oncology/NSABP B-51/RTOG 1304 study of locoregional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy (Abstract GS02-07).
The ASCO Post Staff
Sara A. Hurvitz, MD, of Fred Hutchinson Cancer Research Center, University of Washington, discusses phase III findings of the HER2CLIMB-02 study, which showed the combination of tucatinib and trastuzumab emtansine improved progression-free survival in patients with previously treated, HER2-positive, locally advanced or metastatic breast cancer (including those with brain metastases) (Abstract GS01-10).
